ライフサイエンスコーパス: 123I

1 123I crosstalk into the 99mTc window was 2.79% and was r

2 123I-Ang II formation (as measured by fractional convers

3 123I-Ang metabolites were separated by high-pressure liq

4 123I-Labeled iodoazomycin arabinoside (IAZA) is a marker

5 123I-labeled iodophenylpentadecanoic acid (IPPA) is a sy

6 123I-labeled T84.66 minibodies demonstrated rapid, high

7 [123I] beta-CIT and single photon emission computed tomog

8 [123I]5-iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-

9 sence of systolic thickening (-3.2% +/- 1%), 123I-IPPA defect magnitude (LAD/left circumflex artery [

10 sults of technetium 99m (99mTc)-,iodine 123 (123I)-, and iodine 131 (131I)-labeled anti-CEA antibodie

11 ssing hNIS could be imaged using iodine-123 (123I) and shown to retain iodide for up to 48 hours.

12 y serial gamma-camera imaging of iodine-123 (123I) uptake both in MV-sensitive KAS-6/1 myeloma xenogr

13 tron emission tomography (PET), iodine-123- (123I) and iodine-131 (131I) -metaiodobenzylguanidine (MI

14 Uptake of radiolabeled (131I [n=2], 123I [n=1], or 111In [n=10]) antibody to MHC-II increase

15 ers labeled with 2beta-carbomethoxy-3beta-(4-123I-iodophenyl)tropane (123I-beta-CIT); nine healthy hu

16 The SPECT radioligand, 3-quinuclidinyl-4-[123I]iodobenzilate ([123I]IQNB), binds to muscarinic rec

17 erebral injection of the thymidine analog 5-[123I]iodo-2'-deoxyuridine ([123I]IUdR).

18 for cortex, regional brain levels of (-)-5-[123I]IBVM ((-)-[123I]5) at 4 h exhibited a linear correl

19 h 12.44% for the uncorrected image and 3.70% 123I crosstalk in the 99mTc image.

20 nAChR agonist radiotracer [123I]5-IA-85380 ([123I]5-IA), we imaged beta2*-nAChR availability in human

21 n brain-slice phantom was filled with 99mTc, 123I or a 3:1 mixture of the two isotopes.

22 everal radionuclides of interest: 90Y, 99mTc,123I and 131I.

23 activity quantitation in simultaneous 99mTc/123I SPECT.

24 ts to clinicians that a positive (abnormal) [123I]FP-CIT SPECT scan, even in a patient with an EPMS,

25 trial was to assess the use of a fatty acid, 123I-iodophenylpentadecanoic acid (IPPA), to identify vi

26 High specific activity [123I]ZIET was synthesized in 33% radiochemical yield (de

27 In addition, [123I]IUdR has a potential role in the scintigraphic dete

28 We studied the feasibility of administering [123I]IBZM as a bolus plus continuous infusion over 8 hr

29 After locoregional administration, [123I]IUdR and [125I]IUdR localize within tumor, clear ra

30 data, were obtained for each volunteer after 123I-IAZA administration.

31 erformed at either 0-7 hr or 18-24 hr after [123I]beta-CIT injection permits calculation of reliable

32 abeled tracer and neurotransmission using an 123I-labeled tracer.

33 lular range Auger electron emitters 125I and 123I, the thymidine analogue 5-iodo-2'deoxyuridine (IUdR

34 ng using two separate line sources (57Co and 123I); and a set of eight patients with Parkinson's dise

35 iquid chromatography, and 123I-Ang-(1-7) and 123I-Ang II were quantified across the myocardial circul

36 Twenty-four 99mTc and 123I activity distributions were simulated on the basis

37 mal and pathologic studies of both 99mTc and 123I activity estimates were very close with ANN to thos

38 ensitive cells in the GI tract for 99mTc and 123I are tenfold lower; those for 131I are fivefold lowe

39 or the simultaneous acquisition of 99mTc and 123I radiotracer distributions in the brain has been dev

40 or the simultaneous acquisition of 99mTc and 123I SPECT images of the brain.

41 arison, unscattered (U) photons of 99mTc and 123I were recorded.

42 by high-pressure liquid chromatography, and 123I-Ang-(1-7) and 123I-Ang II were quantified across th

43 5 dogs underwent LAD occlusion for 3 h, and 123I-IPPA was injected 60 min after reperfusion.

44 Our protocols for imaging both 131I-MIBG and 123I-MIBG, along with the normal distribution of these c

45 istered 99mTc-based radiopharmaceuticals and 123I-Nal, the interval required for urinary levels of ac

46 in brain imaging (11C, 15O, 18F, 99(m)Tc and 123I) and for three radionuclides showing selective upta

47 essed by CEA concentration, 125I-uptake, and 123I-imaging studies.

48 Both [123I]-FPCIT and [123I]-beta-CIT demonstrated decreased striatal uptake in

49 Therefore, fasting is not necessary before 123I-IPPA SPECT imaging for the assessment of myocardial

50 ding of the D2 radioligand [123I]benzamide ([123I]IBZM) was studied with single photon emission compu

51 [(1-ethyl-2-pyrrolidinyl) methyl]benzamide ([123I]IBZM).

52 Both [123I]-FPCIT and [123I]-beta-CIT demonstrated decreased s

53 y using [123I]IUdR and currently using both [123I]IUdR and [125I]IUdR.

54 61.0 +/- 13.2 yr; H&Y Stage I-II) with both [123I] beta CIT-FP and [18F]FDOPA.

55 verestimates in healthy control subjects by [123I]-FPCIT.

56 time activity curves was used to calculate [123I]-iodobenzovesamicol to vesicular acetylcholine tran

57 purpose of the present study was to compare [123I]-beta-CIT with [123I]-FPCIT in a within-subject des

58 We compared [123I] beta CIT-FP/SPECT and [18F]FDOPA/PET in the assess

59 aseline levels over the 5.5 hr of continued [123I]IBZM administration.

60 SPECT imaging during continuous [123I]IBZM infusion provides a powerful within-scan metho

61 In contrast, 123I-IPPA given early after reperfusion following prolon

62 t, in randomized order and on separate days, 123I-IPPA SPECT myocardial imaging under fasting and non

63 midine analog 5-[123I]iodo-2'-deoxyuridine ([123I]IUdR).

64 The diagnostic yield of planar diagnostic 123I scintigraphy at 24 h was superior to that at 5 h fo

65 and 12 healthy volunteers underwent dynamic [123I]-iodobenzovesamicol SPECT and magnetic resonance (M

66 ectron emitters has antineoplastic effects ([123I]IUdR and [125I]IUdR) in addition to its scintigraph

67 5 min with several concentrations of either [123I]IUdR or [125I]IUdR and their colony survival was me

68 eceived transmission 57Co scans and emission 123I scans after injection of 123I-beta-CIT.

69 radiolabeled with the Auger electron emitter 123I or 125I (*IUdR).

70 When labeled with the Auger electron emitter 123I or 125I, IUdR demonstrates therapeutic efficacy.

71 adiolabeled with the Auger electron emitters 123I and 125I in several animal tumor models.

72 Contamination caused by high-energy 123I decay photons was incorporated.

73 We evaluated [123I]-2 beta-carbomethoxy- 3 beta-(4-fluorophenyl)-N-(1-

74 The final 123I-IPPA activity ratio was significantly greater than

75 For 123I, AW + OSEM yielded a bias of 7% in the cerebellum,

76 rding to patient/body region was 80%/65% for 123I-MIBG and 88%/70% for [18F]FDA-PET.

77 The radiation dose biodistribution for 123I-IAZA was studied to assess and characterize its sui

78 asymmetric with a lower bound at 159 keV for 123I.

79 nvert 57Co attenuation values into those for 123I, based on a pixel-by-pixel comparison of two coregi

80 For [123I]-beta-CIT, the mean Parkinson's disease values repr

81 cy (F[1,25] = 52.1 and 53.0, p < 0.0001 for [123I] beta CIT-FP and [18F]FDOPA, respectively).

82 chniques (r = -0.69 and -0.60, p < 0.04 for [123I] beta CIT-FP and [18F]FDOPA, respectively).

83 controls with a mean of V"3=3.5 and 6.7 for [123I]-beta-CIT (Parkinson's disease and controls, respec

84 8 for [123I]beta-CIT-FP and 7.7 +/- 0.7 for [123I]beta-CIT-FE, showing high in vivo selectivity for t

85 tively) and a mean of V"3=1.34 and 3.70 for [123I]-FPCIT (Parkinson's disease and controls, respectiv

86 cific midbrain activity was 9.1 +/- 1.8 for [123I]beta-CIT-FP and 7.7 +/- 0.7 for [123I]beta-CIT-FE,

87 arkinson's disease patients were higher for [123I]-FPCIT than for [123I]-beta-CIT.

88 expressed as a percent reduction per hr for [123I]-FPCIT.

89 The Do dose rates for [123I]IUdR and [125I]IUdR, respectively, are 18.78 and 1.

90 ients were higher for [123I]-FPCIT than for [123I]-beta-CIT.

91 [123I]beta-CIT-FP and a faster washout for [123I]beta-CIT-FE (14.7% +/- 6.9%).

92 ithin 30 min, with little or no washout for [123I]beta-CIT-FP and a faster washout for [123I]beta-CIT

93 ional brain levels of (-)-5-[123I]IBVM ((-)-[123I]5) at 4 h exhibited a linear correlation (r2 = 0.99

94 Intracoronary (IC) 123I-Ang I was administered to 4 heart transplantation r

95 dy was performed to determine differences in 123I image quality at 5 and 24 h for the detection of re

96 The amphetamine-induced decrease in [123I]IBZM binding potential was significantly greater in

97 tive and negative symptoms and increases in [123I]IBZM specific binding.

98 and, 3-quinuclidinyl-4-[123I]iodobenzilate ([123I]IQNB), binds to muscarinic receptors and has genera

99 ease, NCT00126425; Meta-Iodobenzylguanidine [123I-mIBG] Scintigraphy Imaging in Patients With Heart F

100 phy and the selective 5-HT2A receptor ligand 123I iodinated 4-amino-N-[1-[3-(4-fluorophenoxy)propyl]-

101 s limited to the most commonly used ligand, [123I]beta-CIT, stratification by affection status dramat

102 l, patients with more symptoms showed lower [123I]IBZM specific binding, consistent with competition

103 med by intravenous injection of 191-226 MBq [123I]5-I-A-85380 and image acquisition for 289-367 min.

104 the 1.5-2 h after injection of 185-370 MBq [123I]IACFT.

105 fter oral administration of 56 MBq (1.5 mCi) 123I were concordant in 73% of patients.

106 In protocol 1, 185 MBq (5 mCi) 123I-IPPA were injected intravenously in 19 dogs with 50

107 and 24 hr postinjection of 370 MBq (10 mCi) [123I]beta-CIT.

108 )]- oxo-[1R-(exo-exo)]) and 185 MBq (5 mCi) [123I]iodobenzamide or [123I]iodobenzofuran.

109 aged at 24 hr postinjection 222 MBq (6 mCi) [123I]-beta-CIT and serially from 1-6 hr postinjection 33

110 y from 1-6 hr postinjection 333 MBq (9 mCi) [123I]-FPCIT.

111 d 52% of the control uptake, while the mean [123I]-FPCIT value for Parkinson's disease patients was 3

112 l-4-piperidinyl]-5-iodo-2- methoxybenzamide (123I-5-I-R91150).

113 phenyl)-N-(1-iodoprop-1-en-3-yl)nortropane ([123I]IACFT) for SPECT imaging in an MPTP model of parkin

114 that is well matched to the physical t1/2 of 123I.

115 sured 24 hr after the oral administration of 123I, 3.7-7.4 MBq (0.1-0.2 mCi) with no changes in techn

116 Analysis of 123I transmission images of the nine healthy human contr

117 The dosimetric analysis of 123I-IAZA in 6 healthy volunteers indicated that both di

118 thout corrections for cross-contamination of 123I into the 99mTc window, striatum-to-cerebellum ratio

119 The fractional conversion of 123I-Ang-(1-7) was 0.198+/-0.032 but was reduced to 0.06

120 hod for nonuniform attenuation correction of 123I emission brain images based on transmission imaging

121 h received a nominal 185-MBq (5 mCi) dose of 123I-IAZA administered as a slow (1-3 min) intravenous i

122 on and transmission scans after injection of 123I-beta-CIT.

123 s and emission 123I scans after injection of 123I-beta-CIT.

124 sing a gamma camera after i.p. injections of 123I.

125 amera after i.p. injection of 500 microCi of 123I.

126 versus pretreatment (80%/65%) sensitivity of 123I-MIBG scintigraphy.

127 Values for thyroid uptake of 123I in euthyroid and hyperthyroid patients in Boston ha

128 mors (P-1) which showed no in vivo uptake of 123I, NP-1 tumors accumulated 25-30% of the total 123I a

129 In pulmonary emboli, the absolute uptake of 123I-bitistatin (0.64 +/- 0.17% ID/g) was higher than al

130 g conditions may affect myocardial uptake of 123I-IPPA.

131 ing can be complemented by additional use of 123I-labeled D2/D3 receptor ligand co-injected to assess

132 Striatal accumulation of [123I]IACFT was nearly completely displaceable with unlab

133 rmed after intra-arterial administration of [123I]IUdR in patients with liver metastases and intraves

134 ne-123 fluoropropyl (FP)CIT is an analog of [123I]-beta-CIT and has been shown to achieve peak tracer

135 Analysis of [123I]-FPCIT time-activity curves for specific striatal c

136 ain activity levels, and the application of [123I]IBZM continuous infusion to examine the effects of

137 e healthy male subjects received a bolus of [123I]IBZM followed by a continuous infusion at a bolus (

138 e caused the breakdown of the amide bond of [123I]-31 and rendered this agent obsolete as an in vivo

139 Blood clearance of [123I]IACFT was rapid with a terminal t1/2 of approximate

140 d a similar bolus plus constant infusion of [123I]IBZM.

141 ly 157 +/- 13.7 min after the initiation of [123I]IBZM infusion.

142 ealthy controls obtained after injection of [123I])beta-CIT in part to assess the utility of this tra

143 measures obtained after bolus injection of [123I]beta-CIT 0-7 hr (Day 1) and 18-24 hr (Day 2) after

144 atio measured at 30 min, after injection of [123I]IACFT was significantly higher (p < 0.01) than with

145 5 min) for 3 hr following the injection of [123I]IBZM.

146 4 hr post injection of 360 MBq (9.7 mCi) of [123I]beta-CIT.

147 lia can be acquired with 185 MBq (5 mCi) of [123I]IPT.

148 on of 165 +/- 16 MBq (4.45 +/- 0.42 mCi) of [123I]IPT.

149 The pharmacokinetics of [123I]IUdR locoregionally administered to a human glioma

150 imaging performed at 24 hr postinjection of [123I]beta-CIT permits calculation of reliable and reprod

151 procedures have limited the practicality of [123I]IQNB SPECT imaging.

152 cs, neurobiology, and imaging properties of [123I]IACFT.

153 Radioiodination of [123I]IQNB from our tri-n-butylstannyl precursor is simpl

154 and assumptions about the reversibility of [123I]beta-CIT in striatum.

155 pecificity of scan 89%), the specificity of [123I]FP-CIT SPECT scans was reduced in the FTD group to

156 to radioiodinate the four stereoisomers of [123I]IQNB.

157 ects participated in two kinetic studies of [123I]beta-CIT uptake.

158 ale volunteers was measured with the use of [123I] beta-CIT and single photon emission computed tomog

159 IBI (rest and stress), 123I-/124I-/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 111In-DTPA and 89Sr-SrC

160 o examine the impact of dietary condition on 123I-IPPA metabolic imaging.

161 t 90% of regions that were false negative on 123I-MIBG scintigraphy or [18F]FDA-PET were detected by

162 False-negative results on 123I-MIBG scintigraphy and/or [18F]FDA-PET were not pred

163 renic group, elevated amphetamine effect on [123I]IBZM binding potential was associated with emergenc

164 w of the PET camera were also identified on [123I]MIBG scintigraphic images.

165 visually rating the caudate and putamen on [123I]FP-CIT SPECT scans.

166 participated in one [123I]-beta-CIT and one [123I]-FPCIT SPECT scan separated by 7-21 days.

167 ealthy control subjects participated in one [123I]-beta-CIT and one [123I]-FPCIT SPECT scan separated

168 parison subjects (n=31) participated in one [123I]5-IA-85380 single photon emission computed tomograp

169 Each received one [123I]5-I-A-85380 SPECT scan and an MRI scan.

170 56 rats were injected with GdDTPA-albumin or 123I-GdDTPA-albumin either immediately before reperfusio

171 and 185 MBq (5 mCi) [123I]iodobenzamide or [123I]iodobenzofuran.

172 to assess the performance of beta-methyl-p-[123I]-iodophenyl-pentadecanoic acid (BMIPP) single-photo

173 Whole-body delayed planar [123I]MIBG imaging at 48 hr and SPECT imaging of the ches

174 ll five subjects achieved unchanging plasma [123I]IBZM and striatal brain-activity levels over the 30

175 in addition to its scintigraphic potential ([123I]IUdR and [131I]IUdR), it holds promise for therapy

176 ple radioiodination procedure for preparing [123I]IQNB from a tri-n-butylstannyl precursor in a no-ca

177 primary 99mTc image (130-146 keV), a primary 123I image (152-168 keV) and a secondary 99mTc crosstalk

178 The radioiodines 123I, 124I, 125I and 131I were accommodated as tracers a

179 Specific binding of the D2 radioligand [123I]benzamide ([123I]IBZM) was studied with single phot

180 mography with the nAChR agonist radiotracer [123I]5-IA-85380 ([123I]5-IA), we imaged beta2*-nAChR ava

181 ial of the specific D2 receptor radiotracer [123I] (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-p

182 tomography and the D2 receptor radiotracer [123I]IBZM.

183 and the benzodiazepine receptor radiotracer [123I]iomazenil.

184 (R,S)-[123I]IQNB appears to be the SPECT agent of choice.

185 These findings suggest that serial 123I-IPPA imaging may be useful for assessing myocardial

186 ormal and pathologic studies of simultaneous 123I/99mTc brain SPECT when compensating for all degradi

187 In smokers, [123I]5-IA uptake was significantly higher throughout the

188 yl]tropane (3) with no carrier-added sodium [123I]iodide and hydrogen peroxide in ethanolic HCl.

189 albumin (HSA), 99mTc-MIBI (rest and stress), 123I-/124I-/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 1

190 norepinephrine transporter (NET) substrates [123I]-m-iodobenzylguanidine (MIBG) and [11C]-m-hydroxyep

191 ng selective uptake in the thyroid (99(m)Tc, 123I, and 131I).

192 Of the disintegrins tested, 123I-bitistatin had higher uptake in DVT (0.21 +/- .06%

193 rom striatal tissue 15-20 times faster than [123I]-beta-CIT, and estimates of dopamine transporter lo

194 These results demonstrate that [123I]IACFT is an excellent SPECT ligand for dopamine tra

195 es performed in male rats demonstrated that [123I]1 was selective and specific for SERT.

196 studies performed in rats demonstrated that [123I]ZIET was selective and specific for SERT-rich regio

197 These results indicate that [123I] beta CIT-FP/SPECT can provide quantitative descrip

198 distribution studies in rats indicated that [123I]ZIET enters the brain readily and accumulates in SE

199 Taken together, the data suggests that [123I]16(IMPY) may be useful for imaging A beta aggregate

200 9mTc crosstalk image was subtracted from the 123I image.

201 results showed 1.51% 99mTc crosstalk in the 123I image compared with 12.44% for the uncorrected imag

202 images: results showed 1.3% crosstalk in the 123I image compared with 19.7% for a 10% asymmetric ener

203 ng three experiments with coinjection of the 123I-and 125I-radiolabeled tracer for direct comparison

204 disease biomarkers, brain imaging using the 123I-ioflupane ligand with single-photon emission comput

205 ed from the five control subjects after the [123I]-FPCIT injection for analysis of radiometabolites.

206 16 patients the mean percent decline in the [123I]beta-CIT uptake was significantly greater with levo

207 The sensitivity for each of the [123I]MIBG imaging methods was calculated on a study-by-s

208 ine blood levels were negatively related to [123I]IBZM specific binding.

209 es reductions in striatal uptake similar to [123I]-beta-CIT.

210 NP-1 tumors accumulated 25-30% of the total 123I administered with a biological half-life of 45 h.

211 Final transmural 123I-IPPA LAD/LCX activity ratio (0.99 +/- 0.05) was sig

212 rbomethoxy-3beta-(4-123I-iodophenyl)tropane (123I-beta-CIT); nine healthy human control subjects who

213 -carbomethoxy-3beta-(4-iodophenyl) tropane ([123I]beta-CIT) for measurement of central SERT availabil

214 arboxymethoxy-3-beta-(4-iodophenyl)tropane ([123I]beta-CIT) uptake.

215 arboxymethoxy-3 beta-(4-iodophenyl)tropane ([123I]beta-CIT), were used to determine DA transporter de

216 3 women; aged 19-74 yr) participated in two [123I]beta-CIT SPECT scans separated by 7-14 days.

217 ealthy control subjects participated in two [123I]beta-CIT SPECT scans separated by 7-21 days.

218 on's disease, the Parkinson Study Group used 123I-beta-CIT SPECT.

219 The authors used [123I]5-I-A-85380 single photon emission computed tomogra

220 e last 16 yr, thyroid RIU measurements using 123I were obtained in 671 euthyroid patients and 274 hyp

221 Using [123I]5-I-A-85380 single photon emission computed tomogra

222 n in the thalamus and temporal cortex using [123I]epidepride SPECT.

223 nts with bladder carcinoma, initially using [123I]IUdR and currently using both [123I]IUdR and [125I]

224 ity of quantifying alpha4beta2 nAChRs using [123I]5-I-A-85380 and support the use of V(T)' as an appr

225 rters and supports the feasibility of using [123I]beta-CIT in serial evaluation of human neuropsychia

226 jects and supports the feasibility of using [123I]beta-CIT in the evaluation of disease progression i

227 e-photon emission computed tomography using [123I]iodobenzovesamicol (IBVM), an in vivo marker of the

228 eparation of *IUdR by demercuration whereby [123I/125I/131I]IUdR is synthesized virtually instantaneo

229 under fasting and nonfasting conditions with 123I-IPPA.

230 Patients were injected with 123I-IPPA (4-5 mCi) at rest with imaging performed at 4

231 mpounds could be used as SPECT (labeled with 123I) or PET (labeled with 18F) radiotracers to image th

232 Blood flow was measured with 123I- or 125I-N-isopropyl-p-iodoamphetamine.

233 Images of DVT obtained with 123I-bitistatin were focally positive within 1 hr and im

234 risk area), viability was overestimated with 123I-IPPA, because uptake averaged 64% of normal in the

235 tivity ratios, as is commonly performed with 123I-beta-CIT, these outcome measures showed only small

236 After radiolabeling with 123I, disintegrins were tested for their ability to imag

237 diagnoses, such as Parkinson's disease with (123I)beta-CIT single photon emission computed tomography

238 t study was to compare [123I]-beta-CIT with [123I]-FPCIT in a within-subject design.

239 of beta2*-nAChR binding was conducted with [123I]5-I-A-85380 on prefrontal cortex samples from 14 de

240 These data suggest that SPECT imaging with [123I]-FPCIT visually demonstrates reductions in striatal

241 re is increasing evidence that imaging with [123I]FP-CIT SPECT is helpful in differentiating dementia

242 ts of SPECT and delayed planar imaging with [123I]MIBG in neuroblastoma have not yet been fully estab

243 Four healthy volunteers were injected with [123I]-beta-CIT-FP and another four were injected with [1

244 -CIT-FP and another four were injected with [123I]beta-CIT-FE.

245 ient with a cystic glioma was injected with [123I]IUdR.

246 residual nicotine would not interfere with [123I]5-IA binding to the beta2*-nAChR as approximately 7

247 d decline in striatal uptake was noted with [123I] beta CIT-FP (r = -0.56, p < 0.04) but not with [18

248 inetics, and the good results obtained with [123I]ZIET in rats support the candidacy of [11C]ZIET for

249 sympathetic innervation and perfusion with [123I]metaiodobenzylguanidine (MIBG) and 201Tl, respectiv

250 fication of extrastriatal D2 receptors with [123I]epidepride.

251 emission computed tomography scanning with [123I]2beta-carbomethoxy-3beta-(4-iodophenyl) tropane ([1

252 seven patients underwent scintigraphy with [123I]meta-iodobenzylguanidine (MIBG), and two patients w